Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "Fibrate" patented technology

In pharmacology, the fibrates are a class of amphipathic carboxylic acids. They are used for a range of metabolic disorders, mainly hypercholesterolemia (high cholesterol), and are therefore hypolipidemic agents.

Nanoparticulate fibrate formulations

The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed / fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
Owner:ALKERMES PHARMA IRELAND LTD +1

Nanoparticulate fibrate formulations

The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed / fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
Owner:ALKERMES PHARMA IRELAND LTD +1

Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders

InactiveUS20050101565A1Reducing and avoiding adverse effectBiocideNervous disorderDyslipidemiaFibrate
The invention relates, in part, to pharmaceutical compositions that comprise a combination of pantethine, or a derivative thereof, and a second active agent. Examples of second active agents include, but are not limited to, statins, fibrates, glitazones, biguanides, sulfonylureas, dyslipidemic controlling compounds, small peptides of the invention, and combinations thereof. The invention also relates to methods for treating, preventing, or managing cholesterol, dyslipidemia, and related disorders.
Owner:ESPERION THERAPEUTICS

Liver targeted medicine

The invention relates to the field of biological medicine, and in particular relates to liver targeted medicine. The medicine is chemical micromolecular medicine connecting galactosamine. The chemicalmicromolecular medicine is medicine for treating liver diseases or liver-related diseases. The chemical micromolecular medicine is prepared from but not limited to thyroxine T3, sorafenib, taxol, regorafenib, lamivudine, entecavir, telbivudine, statins, fibrates, niacin, bile acid sequestrants, other hepatitis virus DNA (RNA) polymerase inhibition compounds and the like. The galactosamine is tervalent acetylgalactosamine. The connection is the direct connection of the galactosamine and the chemical micromolecular medicine or the connection through linking fragments; the linking fragments comprise but not limited to carbon chains, disulfide bonds, pyrophosphate diester, cysteic acid, polypeptide and thioether or valine-citrulline. The medicine provided by the invention has the advantages that the liver targeted performance is improved; the medicine curative effect is enhanced; the toxic and side reactions on other non-targeted tissues are few.
Owner:崔坤元

Composition and therapies for hyperlipidaemia-associated disorders

The invention relates to pharmaceutical compositions comprising at least one fibrate and at least one bile acid, and to methods for the treatment of hyperlipidaemia or elevated liver function tests in a patient by administering at least one fibrate and at least one bile acid to the patient.
Owner:BORODY THOMAS JULIUS

Solid dosage form comprising a fibrate and a statin

The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors), which compositions are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e. the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration
Owner:VELOXIS PHARMA

Isomers of inositol niacinate and uses thereof

InactiveUS20090326013A1Reduce cardiovascular riskPrevent liver damageBiocideNervous disorderHMG-CoA reductaseAllo-Inositol
An ester formed from an inositol or an inositol derivative and niacin, wherein the inositol or the inositol derivatives comprises a stereoisomer selected from allo-inositol, cis-inositol, epi-inositol, muco-inositol, neo-inositol, scyllo-inositol, D-chiro-inositol and L-chiro-inositol, or pharmaceutically acceptable salts thereof. Examples of esters include inositol hexaniacinates such as allo-inositol hexaniacinate and cis-inositol hexaniacinate. The esters can be used to treat any disorder that is treatable with niacin therapy such as dyslipidemia, hypercholesterolemia, hyperlipidemia or cardiovascular disease. The esters can be administered with other agents such as HMG-CoA reductase inhibitors, statins, fibrates, activators of peroxisome proliferator activated receptors poli-cosanol, phytosterols, tocotrienols, calcium, bile acid sequestrants, guar gum and free niacin. The invention includes pharmaceutical compositions containing these compounds.
Owner:CONCOURSE HEALTH SCI

Drug for treating or preventing duplication of hypertension with serum hyperuricemia and/or hypercholesterolemia

InactiveCN1972931AOrganic active ingredientsNervous disorderDiseasePotassium canrenoate
The purpose in this invention is to providing drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia that is much frequency among the duplication onset in geriatric diseases. This invention is related to drugs for treating or preventing duplication of hypertension with serum hyperuricemia and / or hypercholesterolemia of which active principles are 2-propyl-3- {[2'-(1H-tetrazole -5-yl) biphenyl -4-yl]methyl}-5, 6, 7, 8-tetrahydrocyclohepta imidazole -4-(3H) - one and that prodrug or that salt. Pratosartan is able to use in combination with one or more than two diuretics chosen from sulfonamide-, phenoxyacetic acid- and thiazide-type diuretics, triamterene, amiloride, spironolactone, potassium canrenoate and traxanox sodium. Also, pratosartan is able to use in combination with one or more than two hypolipidemic drugs chosen from statins, fibrates, cholesterol absorption inhibitors, cholesterol sequestrants and cholesterol excretion enhancers.
Owner:KOTOBUKI PHARMA CO LTD

Composition and therapies for hyperlipidaemia-associated disorders

The invention relates to pharmaceutical compositions comprising at least one fibrate and at least one bile acid, and to methods for the treatment of hyperlipidaemia or elevated liver function tests in a patient by administering at least one fibrate and at least one bile acid to the patient.
Owner:BORODY THOMAS JULIUS

A method for side effect reduction in the use of statins via physiologically synthesized glutathione

Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of subjects suffering from diseases associated with hyperiipidemia and / or hypercholesterolemia. Related embodiments of the present invention relate to treatment and / or reducing the incidence of the side effects of statin therapy comprising administering to a subject in need, a composition comprising a glutathione precursor and a selenium source. Embodiments of the invention also relate to the use of the compositions in combination therapy with other agents such as statins, cholesterol absorption inhibitors, bile acid binding resins, or fibrates. In other embodiments, the invention relates to the use of such compositions comprising the glutathione precursor and the selenium source in the therapy of subjects suffering from erectile dysfunction and / or viral diseases such as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF).
Owner:THE PROIMMUNE

Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin

The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a fibrate, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (b) a statin, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (c) a solvent; (d) a non-miscible liquid; (e) a stabilizer; and (f) water. The fibrate or the statin or both is in a particulate state and / or a solubilized state. Such pharmaceutical formulations are capable of reducing the fed / fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and have improved oral bioavailability.
Owner:NOVAVAX

Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
Owner:MERCK & CO INC +1

Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof

The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
Owner:ARENA PHARMA

Fenofibrate medicament composition

The invention relates to a fibrate drug combination and solves the problem of the low bioavailability of fenofibrate. The drug combination comprises the following materials according to part by weight: 6 to 42 parts of fenofibrate, 60 to 80 parts of polyethylene glycol 6000 or poloxamer 407, 6 to 42 parts of compritol 888 ATO or precirol AT05, 2 to 12 parts of polyethylene glycol glyceryl dilaurate or ethylene glycol monoethyl ether and 2 to 12 parts of cremophor RH40 or cremophor EL. The invention can finish the processes of drug micronization and micronized drug dispersion in one-step operation based on the physical and chemical properties of raw materials and auxiliary materials; the compritol 888 ATO can achieve the purpose of sustaining the drug release owing to the hydrophobicity thereof, and the compritol 888 ATO has the release characteristics of zero-order sustained release at a particular ratio in a continuous and complete state; the hydrophilic matrix formed by polyethylene glycol 6000 can prevent the drug release from being affected by acid and alkali and reduce the possibility of bioavailability difference caused by the individual difference; and the invention has the advantages of simple production process, low cost and controllable quality.
Owner:安徽省食品药品检验研究院

Superfine powder of Fibrates lipid-lowering drug and preparation method therefor

The invention relates to superfine powder of a Fibrates lipid-lowering drug and a preparation method therefor. The Fibrates lipid-lowering drug is a main therapeutic drug for resisting hyperlipidemia, and due to influence resulting from factors such as relatively poor water solubility and the like, the bioavailability of the Fibrates lipid-lowering drug is not high. The method for preparing the superfine powder of the Fibrates lipid-lowering drug, provided by the invention, comprises the steps of applying ultrasonic waves, of which the frequency is 10kHz to 500kHz, the power is 1mW to 5,000W and the sound intensity is 0.1mW / cm<2> to 500W / cm<2>, to a Fibrates lipid-lowering drug containing homogeneous solution so as to rapidly obtain Fibrates lipid-lowering drug crystals, and then, carrying out normal operations such as solid collecting, washing, drying and the like, thereby directly obtaining the superfine powder of the Fibrates lipid-lowering drug. According to the superfine powder prepared by the method, the bioavailability of the drug is improved, the dosage of the drug is reduced, the solubility of the drug is improved, and the drug absorption can be enhanced, so that the application is wider.
Owner:无锡康福特药物科技有限公司 +1

Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin

The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a fibrate, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (b) a statin, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (c) a solvent; (d) a non-miscible liquid; (e) a stabilizer; and (f) water. The fibrate or the statin or both is in a particulate state and / or a solubilized state. Such pharmaceutical formulations are capable of reducing the fed / fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and have improved oral bioavailability.
Owner:NOVAVAX

PPARa AGONIST COMPOSITIONS AND METHODS OF USE

Pharmaceutical particles having an inner portion comprising an agonist of peroxisome proliferator-activated receptor α (PPARα) and a biodegradable polymer; and an outer coating comprising an emulsifier which surrounds the inner portion, wherein the agonist may be a fibrate, and the particle contains at least about 5 wt % to about 25 wt % of the agonist, and wherein the particle has a sustained delayed release of the agonist in a range of at least about 1 to 12 months when in an aqueous solution or physiological environment. The pharmaceutical particles may be used, for example, to treat diseases and conditions such as ocular disorders which benefit from PPARα agonist.
Owner:VIRGINIA COMMONWEALTH UNIV INTPROP FOUND INC +1

Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases

The present invention provides a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and a calcium channel blocker or a fibrate as active ingredients.
Owner:DAEWOONG PHARM CO LTD

Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof

The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
Owner:ARENA PHARMA

Purpose of fibrate medicine, medicine composition, and purpose of composition

InactiveCN111760027AResistance reversal or remissionOrganic active ingredientsMetabolism disorderFibratePharmaceutical drug
The invention discloses a purpose of fibrate medicine, a medicine composition, and a purpose of the composition. The invention discloses the purpose of the fibrate medicine in enhancement of sensitivity of tumor cells or tumor on EGFR-TKIs or reduction of medicine resistance of tumor cells or tumor on EGFR-TKIs. The invention also discloses a synergistic effect of the medicine composition containing the fibrate medicine on treatment of tumor, particularly non-small cell lung cancer.
Owner:CHINA PHARM UNIV

Hydrogen sulfide donor type compound containing 1,2-dithiole-3-thioketone structure and blood fat reducing application thereof

InactiveCN108864040AGood lipid-lowering activitySignificantly anti-lipid peroxidationOrganic chemistryAntipyreticFibrateAntioxidative stress
The invention discloses a hydrogen sulfide donor type compound containing a 1,2-dithiole-3-thioketone structure and blood fat reducing application thereof, and belongs to the technical field of biological medicines. The compound is similar with Fibrates drugs in structure, can reduce level of triglyceride and cholesterol, and has the effect of being broad in spectrum and reducing blood fat. Besides, the compound can slowly release hydrogen sulfide to bring multiple cardiovascular protection effects such as oxidative stress resistance, oxidation resistance improvement and the anti-inflammationeffect into play.
Owner:XI AN JIAOTONG UNIV

Treatment for high cholesterol

InactiveUS20150018384A1Raise the ratioInhibits hydroxylase activityBiocideOrganic chemistryBile acid bindingDecreasing ldl
The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (LDL-C) and / or very low density Opoproiein cholesterol (VLDL-C) in subjects In need thereof by administering a compound that inhibits HIF hydroxylase activity. The method is useful, for reducing LDL cholesterol levels and total cholesterol levels even In subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia.
Owner:FIBROGEN INC

Pharmaceutical composition for reducing blood fat

The invention provides a pharmaceutical composition for reducing blood fat. The pharmaceutical composition is prepared from Bempedoic acid, fibrate lipid-lowering drugs, folic acid and a proper amount of auxiliary materials. The pharmaceutical composition provided by the invention provides an effective medicine for hyperlipidemia patients, and the three medicines are combined for use and have a synergistic effect. In addition, the pharmaceutical composition can be conveniently taken by a patient, the compliance is improved, and the medical cost is reduced.
Owner:深圳市长卿医学研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products